MK-8690

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Colitis UlcerativeColitis ulcerativeUlcerative Colitis

Phase 2

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

RecruitingNCT07463183

Merck Sharp & Dohme LLCColitis Ulcerative, Ulcerative Colitis

Start: 2026-03-24End: 2028-12-21Target: 100Updated: 2026-09-18

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

Not yet recruitingCTIS2025-523479-49-00

Merck Sharp & Dohme LLCColitis ulcerative

Target: 18Updated: 2026-06-23